about
Emergency ultrasound-based algorithms for diagnosing blunt abdominal traumaMicroheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids.The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaPolymorphism of IL-1 receptor antagonist gene: role in cancerPegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of expertsMolecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortiumEfficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapyCholine-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasisGranulosa cell tumor of the ovary: 10 years follow-up data of 65 patients.Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisAltered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.A prognostic gene expression index in ovarian cancer - validation across different independent data sets.Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the TumorY-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Brain metastases from epithelial ovarian cancer: overview and optimal management.Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumAssociation of myeloperoxidase with ovarian cancer.Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancerAn intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.A phase 3 trial of bevacizumab in ovarian cancer.The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
P50
Q24246993-3C930BF2-A24D-40FC-85B3-54BCEDC20B86Q24811949-F30F1B88-A66C-4F1C-BA65-9A67114CE947Q27316757-B2E4C519-1B60-4200-A88D-DF7A13F9FD58Q27853172-38387895-64B8-4BA8-B040-968F17B247B3Q27853285-1A6E7E20-E067-413D-BFB5-789D3019B1B1Q28203359-21F770D2-AE4C-48D4-B619-10DD0966F6D0Q28272162-0D90C814-3820-419D-A955-C672B6248C84Q28275893-62A17AC1-F923-4C34-A97A-92EFB709E005Q28297144-1D631B7B-13A0-4A68-B963-03340EC1E493Q30514230-218FA1DB-48ED-47C9-9AF3-1FC9EFE61081Q30932911-5C43DBED-5144-4FE6-834F-2989C066FA77Q31108673-DFABFDC2-F6AA-4127-B9ED-EFE958AAAC0FQ33236292-5FDC137F-43F9-4341-AEBF-33E8384FCBCEQ33342119-C34C4524-D33D-450B-AAA1-FC9B60357D8EQ33348813-105A6AE0-F647-44D7-9A9E-63A435BCB23AQ33376928-ABE67437-EA09-466A-B4DF-8E190F075BBEQ33380150-9A549C98-CCB9-4F00-9235-49EB56F7506EQ33382867-8F714548-C865-424D-98C2-A5695808AFDCQ33388219-1D861097-C20E-438D-B24E-3B9A1C3401D4Q33393033-264497AA-F1AA-48C3-BB42-905E7638C0AFQ33397929-214FBEEA-4840-4FDB-8D53-56B22D8AC578Q33419209-0E51ED93-BDF3-4912-B69E-DFF55A9DFF82Q33439255-4486A842-CC66-42A8-B2E9-A599541CF965Q33457159-37BD849D-7E70-47B2-889F-7B4307069B83Q33457920-EC9C07A0-9616-4441-9636-6FBBBFED36CAQ33458308-5D8C05E9-AE7B-4A9F-9A95-C6B2623376F5Q33458373-EA080418-4BA2-4E7E-BB5A-1CA5C280EC0CQ33458564-DDEA6268-2555-4D81-83C1-342FED2ACE6DQ33459478-7011F635-046E-4D0F-9212-5107295BA205Q33459521-F20409D4-053A-4989-8BC7-25C2A7C4E76AQ33481570-5EDEE390-392B-4EDC-8286-165564861A7AQ33624809-3FCB0E97-43D8-45EE-982F-60BC0B3084BFQ33689246-78410130-4DDC-498C-BC58-CC5750A1FC77Q33750749-B7BA92C4-16F1-4A59-859C-BCCCBE3B81BBQ33829751-FE79C93A-2D60-4B4F-91F4-44B27FCBB6AAQ33917340-6E406BBE-31AC-4BF1-AF3F-13D76E5B6300Q33960748-FB389FD5-96DE-4882-ADF6-10D738BA87D6Q34030022-52AC24C9-4AEA-4D43-BD81-0C61A711EED1Q34092935-C2023E08-E375-4441-A507-AFF2A4186FE0Q34135353-6108527D-0CC1-4218-BAE2-D49A6D9FD276
P50
description
onderzoeker
@nl
name
Jalid Sehouli
@ast
Jalid Sehouli
@en
Jalid Sehouli
@es
Jalid Sehouli
@sl
type
label
Jalid Sehouli
@ast
Jalid Sehouli
@en
Jalid Sehouli
@es
Jalid Sehouli
@sl
prefLabel
Jalid Sehouli
@ast
Jalid Sehouli
@en
Jalid Sehouli
@es
Jalid Sehouli
@sl